Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company offers agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Revenue projections:

Revenue projections for NATCOPHARM
Revenue projections for NATCOPHARM

With NATCOPHARM's revenue expected to be lower than the previous year, investors may become cautious. Declining revenues often negatively impact the bottom line, reducing profitability and raising concerns among investors about the company's ability to maintain strong financial performance moving forward.

Financial Ratios:

currentRatio 5.586000
forwardPE 23.404083
debtToEquity 3.670000
earningsGrowth 0.053000
revenueGrowth 0.140000
grossMargins 0.844270
operatingMargins 0.368390
trailingEps 105.270000
forwardEps 41.270000

NATCO Pharma Limited's current ratio of 5.586 highlights the company's solid liquidity, indicating that it can easily service its short-term debt. NATCO Pharma Limited's ample cash reserves and current assets ensure that the company is well-positioned to meet its immediate financial liabilities.
NATCOPHARM's Forward PE is within a good range, showing that the stock price compares well to its earnings. This suggests it isn't overpriced and leaves room for growth, making the stock appealing to investors looking for value and growth opportunities.
NATCO Pharma Limited's positive gross and operating margins reflect its ability to generate profits from operations. These margins demonstrate efficient cost control and profitability, indicating strong financial health for the company.
NATCOPHARM's forward EPS being lower than its trailing EPS suggests the company is expected to see reduced profitability in the current financial year compared to the previous one. This signals a potential decline in earnings, raising concerns about future financial performance.

Insider Transactions:

Insider Transactions for NATCOPHARM
Insider Transactions for NATCOPHARM


Recent trading of NATCOPHARM stock saw 20 sales, with market price at 1344.6024963378907 per share.2 purchases of NATCOPHARM were executed, with market price of 851.625.The list of insider transactions is inconclusive, with no evident trend emerging to suggest a notable shift in company behavior or outlook.

Recommendation changes over time:

Recommendations trend for NATCOPHARM
Recommendations trend for NATCOPHARM


With analysts leaning toward a sell bias for NATCOPHARM, investors should be cautious and make decisions based on a wider set of market indicators. This approach will help balance short-term concerns with longer-term market trends, providing a more holistic view of the stock.